Otsuka Raised Its Dividend After a Solid Half-Year-Can ¥1,379B Sales Still Pass the Smell Test?

Otsuka's first half was solid, but the second half does the heavier lifting

Otsuka's first half looks clean on the surface: net sales rose 9.0% to ¥757.5 billion, operating profit increased 8.0%, and profit attributable to owners of parent rose 8.4% to ¥36.98 billion. That is the kind of half-year that passes the smell test, with revenue and profit moving in the right direction at the same time.

The sales story still looks stronger than the earnings story

The full-year setup is where the tension sits. Otsuka still targets ¥1,379.0 billion in 2026 sales, but the profit guide is more modest: operating profit +4.8% to ¥94.3 billion, ordinary profit +5.0%, and profit attributable to owners of parent +0.9% to ¥64.9 billion. In plain English, the revenue outlook is stronger than the earnings outlook.

That matters because investors now have to judge whether the first half was the easier half. If demand stays firm, the current guides could still be met or even topped. If margin pressure returns, strong sales alone will not be enough.

The dividend adds one useful signal. Management revised the full-year payout to ¥105.00 per share, which suggests confidence is real rather than theoretical. But a higher dividend is a confidence marker, not proof that second-half profits will grow faster than revenue.

For now, the evidence supports demand and sales momentum more clearly than it supports a big earnings acceleration.

Otsuka's product mix still passes the basic utility test

That earlier strength still looks credible because Otsuka is mostly selling things people actually use. The group makes pharmaceuticals, functional beverages, and functional foods for better health. That is a grounded mix: pharma needs to keep showing medical utility, while beverages and functional foods need to keep showing up in shopping carts.

Gross profit matters only if operating profit follows

That is why gross profit increased to ¥138.5 billion matters. On its own, the number is not the full story. What matters is what it says about pricing power and product mix. If Otsuka is selling at better prices or shifting toward a healthier mix, gross profit should move ahead cleanly. And if that continues, the company has a better chance of pushing more of its sales growth through to operating profit.

So the next-quarter watchpoint is straightforward: rising gross profit is a good sign only if operating profit starts to follow. If that link breaks, the products still have real-world utility, but some of the financial payoff is still leaking out elsewhere in the cost structure.

The bull case is durability; the bear case is limited leverage

The bull case is simple: Otsuka's demand sources are not tied to one narrow trend. When one category cools, another can keep the line moving. That matters even more because the balance sheet looks clean, with cash and cash equivalents at period-end were ¥258,955 million and an equity ratio of 50.3%. This does not look like a company masking weakness with financial engineering.

The bear case is also fair: utility alone does not create leverage. A diversified health and nutrition business can keep selling useful products and still deliver only modest profit growth.

The next quarter should help clarify which force is stronger: steady consumer utility, or a weaker earnings lever behind sales growth.

What to watch in Otsuka's next quarter

The easy part was confirming the first half looked healthy. The next quarter is about how much of that strength still shows up at the bottom line. With the full-year dividend raised to ¥105.00 per share and the 2026 profit guides still in place, investors have a clear near-term test: is Otsuka building real leverage, or simply selling more?

Positioning: stay interested, but not aggressive

I would stay interested, but not aggressive. The clean setup is to own the upside case only if the next report starts turning sales into operating leverage. If you already hold shares, the dividend increase gives you a reason to keep the position while watching the quarter closely. If you are waiting to start, it makes sense to let the next quarter do some of the convincing.

This is not a complex financial-model trade. It is a "kick the tires" trade. If the next quarter confirms the business is simple, solid, and useful-pharmaceuticals, functional beverages, and functional foods-then the market has less excuse for ignoring it.

The signposts that matter most

On the next call and in the next release, focus on a short list of signposts:

• whether gross profit continues to support better profit conversion
• whether management still treats the full-year 2026 guides as intact
• whether sales strength is translating into operating profit, or staying mostly at the top line

What would weaken the setup

Back off if you see any of these:

• guidance gets quietly softened or management starts acting like the full-year setup is no longer on track
• sales are fine, but profits lag again
• the dividend hike starts to look ahead of the earnings power behind it

With results due after July 31, 2026, the window is short. In the next quarter, Otsuka should keep the momentum going and show investors whether the current full-year framework still holds.